Follow
Anand Kamal Singh
Title
Cited by
Cited by
Year
Differences in DNA condensation and release by lysine and arginine homopeptides govern their DNA delivery efficiencies
A Mann, G Thakur, V Shukla, AK Singh, R Khanduri, R Naik, Y Jiang, ...
Molecular pharmaceutics 8 (5), 1729-1741, 2011
902011
Enhancer reprogramming confers dependence on glycolysis and IGF signaling in KMT2D mutant melanoma
M Maitituoheti, EZ Keung, M Tang, L Yan, H Alam, G Han, AK Singh, ...
Cell reports 33 (3), 2020
552020
Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer
AK Singh*, E Orouji*, AT Raman*, A Sorokin, E Arslan, AK Ghosh, ...
Gut 71 (5), 938-949, 2022
392022
Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy
CJ Terranova, M Tang, M Maitituoheti, AT Raman, AK Ghosh, J Schulz, ...
Cell reports 36 (3), 2021
252021
Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in head and neck squamous cell carcinoma
AA Osman, E Arslan, M Bartels, C Michikawa, A Lindemann, K Tomczak, ...
Clinical Cancer Research 29 (7), 1344-1359, 2023
212023
Evaluation of epigenetic drug targeting of heterogenous tumor cell fractions using potential biomarkers of response in ovarian cancer
AK Singh, N Chandra, SA Bapat
Clinical Cancer Research 21 (22), 5151-5163, 2015
152015
A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses
RR Naik, AK Singh, AM Mali, MF Khirade, SA Bapat
Oncogene 35 (6), 727-737, 2016
142016
Epigenetic Perspective of Immunotherapy for Cancers
S Keshari*, P Barrodia*, AK Singh#
Cells 12 (365), https://doi.org/10.3390/cells12030365, 2023
122023
Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor
AD Bhalla, SM Landers, AK Singh, JP Landry, MG Yeagley, GSB Myerson, ...
Laboratory Investigation 102 (6), 658-666, 2022
82022
Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma
JTH Prit Benny Malgulwar, Carla Danussi, Sharvari Dharmaiah, William Johnson ...
Neuro-Oncology 155 (doi: 10.1093/neuonc/noad155), PMID: 37625115, 2023
6*2023
Transforming the future of treatment for ovarian cancer
Y Dong, J Batra, K Anand, S Bapat, J Clements
Clinical and Experimental Pharmacology 4 (3), Article number: 1571-9, 2014
62014
KMT2D Loss Promotes Head and Neck Squamous Carcinoma Through Enhancer Reprogramming and Modulation of Immune Microenvironment
SC Callahan, M Divenko, P Barrodia, AK Singh, E Arslan, Z Liu, J Yang, ...
Biorxiv, 2021.09. 21.461314, 2021
42021
Enhancer reprogramming in melanoma immune checkpoint therapy resistance
M Maitituoheti, A Shi, M Tang, LL Ho, C Terranova, K Galani, EZ Keung, ...
bioRxiv, 2022.08. 31.506051, 2022
32022
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML
A Singh*, B Kumar*, R Basar, N Uprety, Y Li, H Fan, AKN Cortes, ...
Science Translational Medicine 16 (764), eadp0004, 2024
22024
Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform
Y Jin, T Miyama, A Brown, T Hayase, X Song, AK Singh, L Huang, ...
Cancer Immunology Research 12 (5), 530-543, 2024
12024
Epigenetic scarring leads to irreversible NK cell dysfunction in myeloid malignancies
B Kumar, A Singh, R Basar, N Uprety, Y Li, H Fan, M Shanley, S Acharya, ...
Blood 142 (Supplement 1), 2088-2088, 2023
12023
New cellular models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor
AD Bhalla, SM Landers, AK Singh, MG Yeagley, GSB Meyerson, ...
bioRxiv, 2021.05. 13.443902, 2021
12021
GENE-34. THERAPEUTICALLY TARGETING EPIGENOMIC AND TRANSCRIPTIONAL DYSFUNCTION IN ATRX-DEFICIENT GLIOMA
C Danussi, A Singh, P Pinnamaneni, G Fisher, D Picketts, K Kannan, ...
Neuro-Oncology 21 (Suppl 6), vi104, 2019
12019
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated …
HM Lee, AK Saw, VK Morris, S Napolitano, C Bristow, S Srinivasan, ...
Clinical Cancer Research 30 (22), 5166-5179, 2024
2024
Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer
YL Sasikumar Kotagiri, Nicholas Blazanin, Yuanxin Xi, Yanyan Han, Md ...
Cell Chemical Biology, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–20